Similarly to what was observed for Rituximab, data on patients treated with Ocrelizumab showed that decreased serum Ig levels were linked to a higher likelihood of severe infection and the correlation was more robust with IgG levels compared to IgM or IgA levels [67,97]. This evidence concerns the gene CD40LG and infection.